title: Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
abstract: Failed storage capacity, leading to pulsatile delivery of dopamine (DA) in the striatum, is used to explain the emergence of 'wearing off' and dyskinaesia in Parkinson's disease. In this study, we show that surviving DA neurons in 6-OHDA lesioned rats sprout to re-innervate the striatum, and maintain terminal density until approximately 60% of neurons are lost. We demonstrate that DA terminal density correlates with baseline striatal DA concentration ([DA]). Electrochemical and synaptosome studies in 6-OHDA lesioned rats and primates suggest that impaired striatal DA re-uptake and increased DA release from medial forebrain bundle fibres contribute to maintaining striatal DA levels. In lesioned rats where terminal density fell by 60% or more, L-DOPA administration increased striatal DA levels markedly. The striatal [DA] produced by L-DOPA directly correlated with the extent of dyskinaesia, suggesting that dyskinaesia was related to high striatal [DA]. While sprouting and decreased dopamine uptake transporter function would be expected to contribute to the marked increase in L-DOPA induced [DA], the increased [DA] was most marked when DAergic fibres were >60% denervated, suggesting that other release sites, such as serotonergic fibres might be contributing. In conclusion, the extent of dyskinaesia was directly proportional to the extent of DA terminal denervation and levels of extra-synaptic striatal DA. We propose that sprouting of DA terminals and decreased dopamine uptake transporter function prevent the appearance of Parkinsonian symptoms until about 60% loss of nigral neurons, but also contribute to dysregulated striatal DA release that is responsible for the emergence of dyskinaesia and 'wearing off'.
authors.affiliation: Brain Injury and Repair, Howard Florey Institute, University of Melbourne, Parkville,VIC, 3010, Australia.
authors.forename: Joohyung
authors.initials: J
authors.lastname: Lee
authors.forename: Wen-Mei
authors.initials: WM
authors.lastname: Zhu
authors.forename: Davor
authors.initials: D
authors.lastname: Stanic
authors.forename: David I
authors.initials: DI
authors.lastname: Finkelstein
authors.forename: Marjorie H
authors.initials: MH
authors.lastname: Horne
authors.forename: Jasmine
authors.initials: J
authors.lastname: Henderson
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lawrence
authors.forename: Louise
authors.initials: L
authors.lastname: O'Connor
authors.forename: Doris
authors.initials: D
authors.lastname: Tomas
authors.forename: John
authors.initials: J
authors.lastname: Drago
authors.forename: Malcolm K
authors.initials: MK
authors.lastname: Horne
mesh_terms: D000818:Animals; D002144:Callithrix; D003342:Corpus Striatum / Q000737:chemistry / Q000378:metabolism*; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008474:Medial Forebrain Bundle / Q000378:metabolism / Q000473:pathology; D023421:Models, Animal; D017072:Neostriatum; D009474:Neurons / Q000473:pathology / Q000502:physiology; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D017729:Presynaptic Terminals / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology
chemical_list: D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine